Here’s a thought… There is an awful lot of
overlap in various clinical and morphological features seen in
myeloproliferative disorders. And for some time JAK-2
mutation screening has been becoming more and more of a popular test in the
diagnosis, even though it’s not diagnostic. (About 50% of essential thrombocythaemia patients test positive for the
JAK2 mutation whereas about 97% of polycythemia rubra vera patients).
There’s now a school of thought
that suggests myeloproliferative disorders should be re-classified as JAK-2
positive of JAK-2 negative myeloproliferative disorder. I don’t really know
that much about JAK-2: I shall have to find out more…
No comments:
Post a Comment